- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07345910
Omgeving, pathogenen en gastheerinteracties bij melioidose (DeEPH)
Het decoderen van de triade: de wisselwerking tussen omgeving, ziekteverwekker en gastheer bij melioïdose (DeEPH)
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems in Thailand, Lao PDR, and Cambodia.
The hospital cohort will enroll approximately1,000 patients with positive melioidosis. Participants will be followed at six time points from admission through one year (post-discharge) to capture acute and recovery-phase outcomes, with clinical data collected on demographics, comorbidities, exposures, treatment, adherence, and outcomes.
For each confirmed case, a healthy control will be recruited within two weeks and matched by age, sex, and village of residence. Controls with no symptoms or history of melioidosis will provide a single blood sample at enrolment and will be followed by telephone at 6 and 12 months.
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
This study is funded by the Wellcome Trust. The grant reference number is 323077/Z/24/Z
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
This is a longitudinal, multicentre observational study conducted across three established microbiology units integrated within hospital and community health systems:
- Sunpasitthiprasong Hospital, Ubon Ratchathani, Thailand (MORU);
- Mahosot Hospital, Vientiane, Lao PDR (LOMWRU); and
- Angkor Hospital for Children, Siem Reap, Cambodia (COMRU).
In addition to hospital-based surveillance, a high-risk community in northern Ubon Ratchathani-referred to as the Sandbox Village-will be intensively monitored to capture subclinical infections and to assess environmental factors influencing disease acquisition.
Participant Recruitment and Follow-up
Hospital cohort:
Patients with melioidosis will be recruited at all three hospital sites. The study plans to recruit 1,000 patients, who will be followed longitudinally at six time points: Day 0 (admission), Days 3 and 7 (acute phase), and Days 30, 180, and 365 (recovery phase).
Clinical data collected will include demographic characteristics, underlying comorbidities, environmental exposures, lifestyle and behavioural factors, treatment history, patient-reported medication adherence, and follow-up outcomes.
Healthy controls:
Each patient will be matched with a healthy control recruited within two weeks of diagnosis, based on age, sex, and village of residence. Controls will have no current symptoms or prior history of melioidosis. They will provide a single blood sample at enrolment for DNA extraction and antibody profiling and will be followed up by telephone on Days 180 and 365.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Community cohort:
To complement hospital-based data and to identify subclinical infections, intensive community surveillance will be conducted in the Sandbox Village, a high-incidence area within the Ubon Ratchathani region. All residents (approximately 400 individuals) will be enrolled. DNA samples will be collected at baseline, and serum samples will be obtained every two months over a 42-month period, either at participants' homes or at a central village location, to measure antibody responses to Burkholderia pseudomallei as a proxy for exposure.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Kamolchanok Claire Chewapreecha, PhD
- Telefoonnummer: 662 203 6333
- E-mail: claire@tropmedres.ac
Studie Locaties
-
-
-
Siem Reap, Cambodja
- Nog niet aan het werven
- Cambodia-Oxford Medical Research Unit (COMRU)
-
Contact:
- Paul Turner, MD
- E-mail: Pault@tropmedres.ac
-
-
-
-
-
Vientiane, Laos
- Nog niet aan het werven
- Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU)
-
Contact:
- Elizabeth Ashley, MD
- E-mail: Elizabeth.Ashley@tropmedres.ac
-
-
-
-
-
Ubon Ratchathani, Thailand
- Werving
- Sunpasitthiprosong Hospital
-
Contact:
- Kamolchanok C Chewapreecha, PhD
- Telefoonnummer: 022036333
- E-mail: claire@tropmedres.ac
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Melioidosis patients:
Patients confirmed to have melioidosis.
Healthy controls:
For each confirmed melioidosis case, a healthy control-defined as having no current fever, no evidence of soft tissue infection, and no prior history of melioidosis-will be recruited from satellite blood bank donors within approximately two weeks of case identification. Controls will be matched by age (±5 years), sex, and village of residence.
Sandbox Village residents:
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation.
Beschrijving
Inclusion criteria for melioidosis patients:
- Age ≥20 years
- Positive for Burkholderia pseudomallei from any clinical samples
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for healthy controls:
- Age ≥20 years
- Currently healthy as judged by study doctor
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Inclusion criteria for sandbox residents:
- Age ≥20 years
- Resident of the study area for at least two years, including the follow-up period
- Willing to participate and give informed consent.
Exclusion criteria for melioidosis patients:
- Current tuberculosis (TB) or TB treatment within the past six months
- Documented HIV infection or use of immunosuppressive therapy in the past 12 months
Exclusion criteria for healthy controls:
- History of melioidosis
- Significant acute illness
- Current fever or soft tissue infection
Exclusion criteria for sandbox residents
-N/A
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: COHORT
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
|---|
|
Melioidosis patients
Patients confirmed to have melioidosis |
|
Healthy controls
Healthy controls will be enrolled for each confirmed melioidosis case. A healthy control is defined as an individual with no current fever, no evidence of soft tissue infection, and no prior history of melioidosis. Controls will be recruited within approximately two weeks of case identification and will be matched to cases by age (±5 years), sex, and village of residence. |
|
Sandbox village cohort
All residents of the Sandbox Village, a high-risk area for melioidosis, will be enrolled to monitor disease progression and to evaluate the impact of improved water sanitation. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Ontwikkeling van melioïdose na blootstelling, beoordeeld onder melioïdosegevallen
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Ontwikkeling van melioïdose na blootstelling, beoordeeld onder gezonde controles
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Ontwikkeling van melioidose na blootstelling, beoordeeld onder bewoners van Sandbox Village
Tijdsspanne: 3,5 jaar
|
3,5 jaar
|
|
Sterfte tijdens de acute fase van infectie bij personen met melioidose (melioidosegevallen).
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Aantal heropnames in het ziekenhuis na ontslag bij personen met melioïdose (melioïdosegevallen).
Tijdsspanne: 365 dagen
|
365 dagen
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Veranderingen in ziekteontwikkeling na blootstelling geassocieerd met interacties tussen omgevingsmodificaties.
Tijdsspanne: 3,5 jaar
|
3,5 jaar
|
|
Veranderingen in mortaliteit tijdens de acute fase van infectie na blootstelling in verband met interacties tussen omgevingsmodificaties.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in heropname in het ziekenhuis na herstel in verband met interacties tussen omgevingsaanpassingen.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in ziekteontwikkeling na blootstelling geassocieerd met interacties tussen klinische managementfactoren.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in mortaliteit tijdens de acute fase van infectie na blootstelling geassocieerd met interacties tussen factoren van klinisch management.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in heropname in het ziekenhuis na herstel in verband met interacties tussen factoren van klinisch management.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in ziekteontwikkeling na blootstelling geassocieerd met interacties waarbij genetische gevoeligheid betrokken is.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in mortaliteit tijdens de acute fase van infectie na blootstelling geassocieerd met interacties waarbij genetische gevoeligheid betrokken is.
Tijdsspanne: 365 dagen
|
365 dagen
|
|
Veranderingen in heropname in het ziekenhuis na herstel geassocieerd met interacties met genetische gevoeligheid.
Tijdsspanne: 365 dagen
|
365 dagen
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Kamolchanok Claire Chewapreecha, PhD, Mahidol Oxford Tropical Research Unit
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- MEL25001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The study outputs, including genomic and transcriptomic data and associated metadata, will be valuable for future research. In compliance with the Wellcome Trust's open data policies and to encourage reproducibility, data will be deposited in two repositories:
Human genomic and transcriptomic data: European Genome-Phenome Archive (EGA), under managed access
Bacterial genomic data: European Nucleotide Archive (ENA), open access
Pseudonymised metadata, including participant demographics and microbiological findings, will be shared with qualified researchers in accordance with the General Data Protection Regulation (GDPR). No personally identifiable information will be shared, and participants will not be identifiable from any released data.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .